© Copyright RiverVest® All Rights Reserved.
Pascal Krotee, Ph.D. is a principal at RiverVest Venture Partners, where she focuses on sourcing and conducting due diligence on prospective investments while providing operational support across the firm’s biopharmaceutical and medical device portfolios.
RiverVest has an extraordinary track record of creating and investing in groundbreaking and successful technologies that change patients' lives for the better. They have achieved these results by putting collaboration, innovation, and transparency above all else. I am thrilled to be part of this team."
Pascal Krotee,
Ph.D.
PRINCIPAL
SAN DIEGO, CALIFORNIA
JOINED IN 2021
Pascal Krotee, Ph.D., joined RiverVest in 2021 as a senior associate and was promoted to principal in 2023. Based in San Diego, Pascal focuses on sourcing and conducting due diligence on prospective investments while providing operational support across the firm’s biopharmaceutical and medical device portfolios. She is currently a board member at a stealth RiverVest portfolio company and a board observer at Atalanta Therapeutics and Biolinq. She previously served on the Board of Directors of Bluejay Therapeutics through its acquisition by Mirum Pharmaceuticals in January 2026 and as a board observer at Avalyn Pharma (NASDAQ: AVLN).
Prior to joining RiverVest, Pascal was an investment associate at Kairos Ventures, where she focused on life sciences investments. During her time at Kairos, she sourced new investment opportunities, led due diligence, and served on the boards of several portfolio companies.
Pascal earned a Ph.D. in Molecular Biology from UCLA, where her research focused on the atomic structures of proteins associated with Alzheimer’s disease and type 2 diabetes, as well as the development of compounds to inhibit these targets. Prior to graduate school, she worked as a junior specialist at the Development Biology Center at the University of California, Irvine, where she earned a B.S. in Developmental and Cell Biology with a Minor in Business Management.
She was named a 2023 recipient of Biocom California’s Life Science Catalyst Award, recognizing her as a top-ten life science trailblazer under the age of 40 in California.